Age-related macular degeneration (AMD) is a macular degenerative eye disease, the major cause of irreversible loss of central vision. In this review, we highlight current progress and future perspectives of novel and investigational therapeutic strategies in the drug pipeline, including anti-vascular endothelial growth factor (VEGF) agents, bispecific antibodies, biosimilars, small molecules, gene therapy, and long-acting drug delivery strategies for both dry and wet AMD. We anticipate that biologics with dual functionalities and combined therapies with long-acting capabilities will lead the wet AMD pipeline. Sustained-release platforms also show potential. However, significant breakthroughs are yet to be made for dry AMD. The personalized approach might be well suited in the scenario of diverse genetic variations in both conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drudis.2022.04.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine learning-enabled virtual screening indicates the anti-tuberculosis activity of aldoxorubicin and quarfloxin with verification by molecular docking, molecular dynamics simulations, and biological evaluations.
Brief Bioinform
November 2024
Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing 100020, China.
Drug resistance in Mycobacterium tuberculosis (Mtb) is a significant challenge in the control and treatment of tuberculosis, making efforts to combat the spread of this global health burden more difficult. To accelerate anti-tuberculosis drug discovery, repurposing clinically approved or investigational drugs for the treatment of tuberculosis by computational methods has become an attractive strategy. In this study, we developed a virtual screening workflow that combines multiple machine learning and deep learning models, and 11 576 compounds extracted from the DrugBank database were screened against Mtb.
View Article and Find Full Text PDFExploring a Novel Outcome Measure of Symptom Progression in Knee Osteoarthritis Utilizing a Large Randomized Trial.
Osteoarthritis Cartilage
December 2024
Formation Bio, Inc., Research and Development, New York City, NY, USA; Caduceus Biomedical Consulting, LLC, Durham, NC, USA; Duke University School of Medicine, Department of Medicine, Division of Rheumatology, Durham, NC, USA.
Objectives: Explore a newly defined composite measure of symptom progression for knee osteoarthritis (KOA) in a large, randomized study of a potential disease-modifying osteoarthritis drug (DMOAD).
Design: Using longitudinal KOA studies, a potential composite endpoint of time to symptom progression was defined as the first occurrence of worsening of WOMAC Pain of ≥10 points with no improvement (≤9 point decrease) in WOMAC Function (0-100 scale). A post hoc analysis explored discrimination and association with structural outcomes in the sprifermin FORWARD trial through Years 3 and 5.
Influenza vaccination for children in Europe: The health of every child matters.
Vaccine
December 2024
Scientific Advisor and Emeritus Director, National Influenza Centre, Valladolid, 47010, Spain.
GPC-3 in hepatocellular carcinoma; A novel biomarker and molecular target.
Exp Cell Res
December 2024
Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Department of Cellular and Molecular Biology, Faculty of Sciences and Advanced Technology in Biology, University of Science and Culture, Tehran, Iran. Electronic address:
Article Synopsis
- Hepatocellular carcinoma (HCC) is a significant global health concern, characterized by late diagnosis and high recurrence rates, necessitating early detection through specific biomarkers.
- Glypican-3 (GPC-3) is identified as a promising biomarker for HCC, being overexpressed in various tumors, which opens up opportunities for targeted therapies to enhance treatment outcomes.
- Recent advancements in GPC-3-targeted therapies, such as bi-specific antibodies and CAR T cell therapies, underscore its potential as both a diagnostic and therapeutic tool in the fight against HCC.
Exploring Drug Repurposing for Interstitial Cystitis/Bladder Pain Syndrome: Defining Novel Therapeutic Targets.
Neurourol Urodyn
December 2024
Faculty of Medicine, Department of Urology, Hacettepe University, Ankara, Türkiye.
Introduction: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating pain condition of unknown etiology. Effective therapies for this condition could not have been developed in the last century. Drug repurposing is a practical strategy for enhancing patient access to successful therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!